Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients
Open Access
- 6 February 2021
- Vol. 9 (2), 133
- https://doi.org/10.3390/vaccines9020133
Abstract
Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (Montanide™) plus imiquimod (Aldara™) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-γ ELISpot assays and flow cytometry for CMV-specific CD8+ T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I–II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8+ T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned.Funding Information
- Else Kröner-Fresenius-Stiftung (2014_A51)
This publication has 35 references indexed in Scilit:
- Human Cytomegalovirus and Kidney Transplantation: A Clinician's UpdateAmerican Journal of Kidney Diseases, 2011
- Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir ProphylaxisAmerican Journal of Transplantation, 2010
- High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft functionTransplant Immunology, 2009
- Vaccine Prevention of Maternal Cytomegalovirus InfectionThe New England Journal of Medicine, 2009
- Aspects of Immune Dysfunction in End-stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2008
- Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult SubjectsThe Journal of Infectious Diseases, 2008
- Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical TrialAmerican Journal of Transplantation, 2008
- Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survivalKidney International, 2004
- Cytomegalovirus infection status predicts progression of heart-transplant vasculopathyTransplantation, 2003
- Diagnostic accuracy of coronary angiography and risk factors for post–heart-transplant cardiac allograft vasculopathyTransplantation, 2003